{
  "schema_version": 1,
  "nct_id": "NCT07776613",
  "title": "A Study of Romosozumab in People With Breast Cancer and Osteoporosis",
  "status": "RECRUITING",
  "conditions": [
    "Breast Cancer",
    "Metastatic Breast Cancer (MBC)"
  ],
  "source": {
    "name": "ClinicalTrials.gov",
    "nct_id": "NCT07776613",
    "url": "https://clinicaltrials.gov/study/NCT07776613",
    "retrieved": "2026-11-16",
    "modified": "Eligibility criteria structured and coded (SNOMED CT, LOINC, RxNorm) by ChartStays from the ClinicalTrials.gov text; the original text is kept unchanged in eligibility.criteria_text. Criteria curated by the project team, not reviewed by clinicians; pre-screening only.",
    "last_update_posted": "2026-08-20"
  },
  "eligibility": {
    "criteria_text": "Inclusion Criteria:\n\n* ≥18 years of age at the time of giving informed consent;\n* Patients diagnosed with hormone-receptor positive (ER/PR \\>1%) metastatic breast cancer to bones on any endocrine therapy with or without targeted therapy (i.e. CDK 4/6 inhibitors, PI3K inhibitors, anti-HER2-therapy);\n* Evidence of osteoporosis on dual X-ray absorptiometry (DXA) scan; must following:\n* osteoporosis on dual X-ray absorptiometry (DXA) scan; or history of fragility fracture of the spine or hip; or of morphometric spine fracture;\n\nExclusion Criteria:\n\n* Prior therapy with a bone-modifying agent (intraveous bisphosphonates or subcutaneous denosumab) for metastatic bone disease;\n* 25 (OH) vitamin D levels \\< 20 ng/mL; Vitamin D repletion will be permitted and subjects will be be rescreened once 25 (OH) vitamin D level ³ 20 ng/mL;\n* History of myocardial infarction or stroke within the preceding year;\n* Current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range per institutional standard (\\<8.5 or \\>10.5 mg/dL); Calcium repletion will be permitted and subjects will be be rescreened once values are within the institutional standard.\n* History of non-healed dental or oral surgery;\n* History of osteonecrosis of the jaw",
    "sex": "FEMALE",
    "minimum_age": "18 Years",
    "maximum_age": null,
    "healthy_volunteers": false
  },
  "structured": [
    {
      "id": "inc-0a",
      "type": "inclusion",
      "kind": "age",
      "label": "Age 18 years or older",
      "source_text": "ClinicalTrials.gov age limits: 18 Years minimum, none maximum",
      "min": 18,
      "max": null,
      "unit": "years"
    },
    {
      "id": "inc-0b",
      "type": "inclusion",
      "kind": "sex",
      "label": "Female participants",
      "source_text": "ClinicalTrials.gov sex: FEMALE",
      "sex": "female"
    },
    {
      "kind": "condition",
      "label": "Breast cancer",
      "primary": true,
      "codes": {
        "snomed": [
          "254837009"
        ]
      },
      "note": "Hormone-receptor status and bone metastases are not checked.",
      "id": "inc-2a",
      "type": "inclusion",
      "source_text": "Patients diagnosed with hormone-receptor positive (ER/PR >1%) metastatic breast cancer to bones on any endocrine therapy with or without targeted therapy (i.e. CDK 4/6 inhibitors, PI3K inhibitors, anti-HER2-therapy);"
    },
    {
      "kind": "condition",
      "label": "Osteoporosis or history of osteoporotic fracture",
      "codes": {
        "snomed": [
          "64859006",
          "443165006"
        ]
      },
      "note": "DXA evidence and morphometric spine fractures are not checked.",
      "id": "inc-4a",
      "type": "inclusion",
      "source_text": "osteoporosis on dual X-ray absorptiometry (DXA) scan; or history of fragility fracture of the spine or hip; or of morphometric spine fracture;"
    }
  ],
  "free_text": [
    {
      "id": "inc-2",
      "type": "inclusion",
      "text": "Patients diagnosed with hormone-receptor positive (ER/PR >1%) metastatic breast cancer to bones on any endocrine therapy with or without targeted therapy (i.e. CDK 4/6 inhibitors, PI3K inhibitors, anti-HER2-therapy);"
    },
    {
      "id": "inc-3",
      "type": "inclusion",
      "text": "Evidence of osteoporosis on dual X-ray absorptiometry (DXA) scan; must following:"
    },
    {
      "id": "inc-4",
      "type": "inclusion",
      "text": "osteoporosis on dual X-ray absorptiometry (DXA) scan; or history of fragility fracture of the spine or hip; or of morphometric spine fracture;"
    },
    {
      "id": "exc-1",
      "type": "exclusion",
      "text": "Prior therapy with a bone-modifying agent (intraveous bisphosphonates or subcutaneous denosumab) for metastatic bone disease;"
    },
    {
      "id": "exc-2",
      "type": "exclusion",
      "text": "25 (OH) vitamin D levels < 20 ng/mL; Vitamin D repletion will be permitted and subjects will be be rescreened once 25 (OH) vitamin D level ³ 20 ng/mL;"
    },
    {
      "id": "exc-3",
      "type": "exclusion",
      "text": "History of myocardial infarction or stroke within the preceding year;"
    },
    {
      "id": "exc-4",
      "type": "exclusion",
      "text": "Current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range per institutional standard (<8.5 or >10.5 mg/dL); Calcium repletion will be permitted and subjects will be be rescreened once values are within the institutional standard."
    },
    {
      "id": "exc-5",
      "type": "exclusion",
      "text": "History of non-healed dental or oral surgery;"
    },
    {
      "id": "exc-6",
      "type": "exclusion",
      "text": "History of osteonecrosis of the jaw"
    }
  ],
  "requested_fields_for_inquiry": [
    "age",
    "sex",
    "conditions"
  ],
  "curation": {
    "method": "manual"
  }
}
